Seeking Alpha

Shares of Amarin (AMRN +2.1%) return to earth since spiking higher earlier this morning after...

Shares of Amarin (AMRN +2.1%) return to earth since spiking higher earlier this morning after its marketing website inadvertently circulated a report that Amarin's AMR101, or Vascepa, will be approved. The company acknowledged the error, saying that says no determination on AMR101 NDA has yet been made by the FDA, adding that information on the site was outdated and should not be relied on.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs